NanoViricides Inc (NNVC)

[rearden]

Yeah, it's a lot like this June 30, 2008 PR:


NanoViricides' Anti-EKC Drug Candidate to Be Studied in Japan

Mon Jun 30, 2008 7:00am EDT
* Reuters is not responsible for the content in this press release.

Renowned Japanese Corneal Researcher Professor Tsubota to Confirm
NanoViricides Ekc-Cide(TM) Animal Study Results
WEST HAVEN, Conn.--(Business Wire)--
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that
an internationally renowned Japanese ophthalmologist and corneal
researcher, Kazuo Tsubota, MD, PhD, has agreed to perform confirmatory
animal efficacy studies of the nanoviricide anti-EKC drug candidate,
EKC-Cide(TM), against EKC (epidemic kerato-conjunctivitis) in Japan.
Dr. Tsubota is currently Professor and Chairman of the Department of
Ophthalmology at Keio University School of Medicine in Tokyo, Japan.

"NanoViricides' study of clinical efficacy of EkcCide, is very
significant. Their study conclusively demonstrated clearance of the
severe pink eye symptoms," said Dr. Tsubota, after a discussion with
the Company scientists in a meeting in Boston last week. He commented,
"EKC and herpes virus infections of the eye are important medical
problems in Japan, and Japanese pharmaceutical companies have a strong
interest in potential treatments," He continued by saying, "I am very
pleased to have the opportunity to confirm the studies in Japan. This
is the first step towards obtaining Japanese regulatory approval."

EKC is a severe and contagious viral infection of the eye in
humans which can lead to severe visual impairment. Viral EKC is
primarily caused by adenoviruses, although some other viruses may also
be the causative agent in humans. There is no currently available
treatment for viral EKC.

The Company has previously reported that EkcCide was shown to
cause rapid and clear clinical recovery of infected animal eyes in a
study conducted by a renowned US ophthalmologic Institute. The
infection in this study was caused by adenovirus 5, supplied by the
Centers for Disease Control and Prevention (CDC). Representative
photographs are posted on the Company's website
(www.nanoviricides.com).

The Company anticipates that the eye-drop formulation of the
broad-spectrum nanoviricide drug candidate which was successful
against adenoviral EKC may have significant potential against other
viral EKC and the less severe viral conjunctivitis diseases as well.
Common viral conjunctivitis is highly contagious and occurs primarily
in schools and other crowded settings, as well as in
immuno-compromised populations. While the Company currently has no
approved product for the treatment of EKC and viral conjunctivitis,
the treatment and prophylaxis market for EKC and other viral causes of
conjunctivitis is expected to be in the order of several billion
dollars annually.

http://www.reuters.com/article/2008/06/30/idUS99475+30-Jun-2008+BW20080630